Breast CancerPhase 1NCT07660055
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
A Phase 1 study testing [68Ga]Ga-DWJ155 and [177Lu]Lu-DWJ155 in people with Breast Cancer and Non-small Cell Lung Cancer (NSCLC), run by Novartis Pharmaceuticals at 5 sites in 4 countries.
Trial summary
The purpose of this phase I study is to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of [177Lu]Lu-DWJ155 and the safety and imaging properties of [68Ga]Ga-DWJ155 in patients with histologically or cytologically confirmed advanced HER2+, HR+/HER2-negative, or triple negative breast… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer
- What is being tested?
- [68Ga]Ga-DWJ155 and [177Lu]Lu-DWJ155
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 156 participants
- Where
- 5 sitesin 4 countries
- Study dates
- 16 Jun 2026to 24 May 2032
- Phase
- Phase 1
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female patients age ≥ 18 years.
- Patients with one of the following histologically or cytologically confirmed and documented malignancies who have progressed on or been intolerant to standard of care therapy, and are not considered appropriate for any standard therapy with proven benefit, in the investigator's judgment:
- Dose Escalation:
- Advanced HER2+ breast cancer with disease progression after at least two prior lines of systemic therapy in the advanced setting
- Advanced HR+/HER2-low breast cancer with disease progression after prior therapy in the advanced setting
- Advanced NSCLC without actionable genetic alterations (AGAs) with disease progression after prior therapy in the advanced setting
Show all 19Show fewer
- Advanced NSCLC with AGAs who have received prior treatment
- Measurable disease as determined by RECIST version 1.1.
- Dose Expansion:
- Advanced HER2+ breast cancer with disease progression after at least two prior lines of systemic therapy in the advanced setting
- Advanced HR+/HER2-low breast cancer with disease progression after prior therapy in the advanced setting
- Advanced HR+/HER2 0 breast cancer with disease progression after prior therapy in the advanced setting
- Advanced HR-/HER2-low breast cancer with disease progression after prior therapy in the advanced setting
- Advanced HR-/HER2 0 breast cancer with disease progression after prior therapy in the advanced setting
- Advanced NSCLC with AGAs, who have received prior treatment
- Advanced NSCLC without known AGAs who have received prior treatment.
- Advanced gastric/GEJ cancer with HER2 IHC 3+ or 2+ (ISH + or -), following disease progression after prior therapy in the advanced setting
- Advanced bladder cancer following disease progression after prior therapy in the advanced setting
- Measurable disease as determined by RECIST version 1.1.
Who cannot join
- Out-of-range laboratory values defined as:
- Creatinine clearance < 60 mL/min (calculated using CKD-EPI 2021 formula, or measured)
- Total bilirubin > 1.5 x ULN (except for patients with Gilbert's syndrome who are excluded if total bilirubin >3.0 x ULN) or direct bilirubin > 1.5 x ULN
- Alanine aminotransferase (ALT) > 3 x ULN, except for patients with tumor involvement of the liver who are excluded if ALT > 5 x ULN
- Aspartate aminotransferase (AST) > 3 x ULN, except for patients with tumor involvement of the liver who are excluded if AST > 5 x ULN
- Lipase > 1.5 x ULN
Show all 22Show fewer
- Absolute neutrophil count (ANC) < 1.5 x 109/L
- Hemoglobin < 9 g/dL
- Platelet count < 100 x 109/L
- Initiation of hematopoietic colony stimulating factors, thrombopoietin mimetics, or erythroid stimulating agents initiated ≤ 2 weeks prior to imaging agent administration.
- Use of transfusion support ≤4 weeks prior to imaging agent administration.
- Impaired cardiac function or clinically significant cardiac disease.
- Unmanageable urinary tract obstruction or urinary incontinence.
- Any serious uncontrolled infection (acute or chronic).
- Pregnant or breastfeeding women.
- Treatment with any of the following anti-cancer therapies prior to imaging agent administration within the stated timeframes:
- Prior treatment with any therapeutic radiopharmaceutical
- < 10 half-lives for any imaging radiopharmaceutical
- ≤ 4 weeks for external beam radiation therapy (EBRT) or brachytherapy
- ≤ 6 months for lung-directed external beam radiotherapy
- Patients with non-tumor uptake of [68Ga]Ga-DWJ155 in tissues or organs that, in the opinion of the investigator, increases the risk associated with [177Lu]Lu-DWJ155 treatment.
- Other protocol-defined inclusion/exclusion criteria may apply.
Trial locations and contacts
5 sites in 4 countries. Contact the study team or a site near you to ask about taking part.
Novartis Pharmaceuticals contact
5 sites in 4 countries
Canada2 sites, 2 recruiting
- Recruiting
Novartis Investigative Site
Montreal, Quebec, H2X 0A9
- Recruiting
Novartis Investigative Site
Montreal, Quebec, H4A 3J1
United States1 site, 1 recruiting
- Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska, 68130
Marlene Bridwell, +1 402 691 6972, mbridwell@nebraskacancer.com
Ralph Hauke
Australia1 site, 1 recruiting
- Recruiting
Novartis Investigative Site
Darlinghurst, New South Wales, 2010
Japan1 site, 1 recruiting
- Recruiting
Novartis Investigative Site
Kashiwa, Chiba, 2778577
About this study
Official title: A Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-DWJ155 and Safety and Imaging Properties of [68Ga]Ga-DWJ155 in Patients With Solid Tumors
The purpose of this phase I study is to evaluate the safety, tolerability, dosimetry, and preliminary anti-tumor activity of [177Lu]Lu-DWJ155 and the safety and imaging properties of [68Ga]Ga-DWJ155 in patients with histologically or cytologically confirmed advanced HER2+, HR+/HER2-negative, or triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), HER2-3+ or 2+ (ISH positive or negative) gastric/gastroesophageal junction (GEJ) cancer, and bladder cancer.
Read the detailed description
The study will be done in two parts. The first part is called "escalation" and the second part is called "expansion". In both parts of the study, patients will initially be imaged with a [68Ga]Ga-DWJ155 positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) scan. In the escalation part, different doses of [177Lu]Lu-DWJ155 will then be tested to identify recommended dose(s) (RD(s)) for further evaluation. The expansion part of the study will examine the safety and preliminary efficacy of [177Lu]Lu-DWJ155 at the RD(s) determined during the escalation part.
In both parts, there will be a safety follow-up period after the last [177Lu]Lu-DWJ155 administration.
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer
- Being tested
- [68Ga]Ga-DWJ155, [177Lu]Lu-DWJ155
- Keywords
- Breast cancer, Non-small cell lung cancer (NSCLC), Bladder cancer, Gastric/gastroesophageal junction (GEJ), Radioligand therapy (RLT), [177Lu]Lu-DWJ155, [68Ga]Ga-DWJ155, Human Epidermal Growth Factor Receptor 2 (HER2), FML539, FKL480
- Medical subject headings
- Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Urinary Bladder Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
[68Ga]Ga-DWJ155Diagnostic test
Also called FKL480
Radioligand imaging agent
[177Lu]Lu-DWJ155Drug
Also called FML539
Radioligand therapy
| Study group | Role | What they receive |
|---|---|---|
| Dose Escalation | Experimental | Patients will receive [68Ga]Ga-DWJ155 and, if eligible, [177Lu]Lu-DWJ155. In this part, multiple dose levels of [177Lu]Lu-DWJ155 will be evaluated. Receives: Diagnostic Test: [68Ga]Ga-DWJ155; Drug: [177Lu]Lu-DWJ155 |
| Dose Expansion | Experimental | Patients will receive [68Ga]Ga-DWJ155 and, if eligible, [177Lu]Lu-DWJ155 at the recommended dose established during the dose escalation part. Receives: Diagnostic Test: [68Ga]Ga-DWJ155; Drug: [177Lu]Lu-DWJ155 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) of [177Lu]Lu-DWJ155
Incidence and severity of AEs and SAEs, including changes in laboratory values, vital signs, echocardiograms (ECGs), and imaging assessments qualifying and reported as AEs.
Measured: Up to approximately 53 months
Incidence of dose-limiting toxicities (DLTs) of [177Lu]Lu-DWJ155
A DLT is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 assessed as unrelated to disease, disease progression, inter-current illness/injury or concomitant medications that occurs within the first treatment cycle. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.
Measured: Up to 6 weeks
Frequency of dose interruptions and reductions [177Lu]Lu-DWJ155
Number of participants with dose interruptions and/or reductions to assess the tolerability.
Measured: 11 months
Dose intensity [177Lu]Lu-DWJ155
Dose intensity defined as the ratio of actual cumulative dose received and actual duration of exposure
Measured: 11 months
Secondary outcomes (14)
Overall Response Rate (ORR) per RECIST v1.1
ORR is defined as the proportion of patients with a best overall response (BOR) of complete response (CR) or partial response (PR) as per local review and according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
Measured: Up to approximately 53 months
Disease Control Rate (DCR) per RECIST v1.1
DCR is defined as the proportion of patients with a BOR of CR, PR, or stable disease (SD) as per local review and according to RECIST v1.1.
Measured: Up to approximately 53 months
Duration of Response (DOR) per RECIST v1.1
DOR is the time between the first documented response (CR or PR) and the date of progression as per local review and according to RECIST v1.1, or death due to any cause.
Measured: Up to approximately 53 months
Progression-Free Survival (PFS) per RECIST v1.1
PFS is defined as the time from the date of start of treatment to the date of the first documented progression as per local review and according to RECIST v1.1 or death due to any cause.
Measured: Up to approximately 53 months
Area under the concentration-time curve (AUC) of [177Lu]Lu-DWJ155
The pharmacokinetic (PK) analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. AUC will be determined by non-compartmental methods.
Measured: From pre-dose up to 168 hours after the end of the infusion on Day 1
Systemic clearance (CL) of [177Lu]Lu-DWJ155
The PK analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. CL will be determined by non-compartmental methods.
Measured: From pre-dose up to 168 hours after the end of the infusion on Day 1
Maximum observed concentration (Cmax) of [177Lu]Lu-DWJ155
The PK analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. Cmax will be determined by non-compartmental methods.
Measured: From pre-dose up to 168 hours after the end of the infusion on Day 1
Volume of distribution during the terminal phase (Vz) of [177Lu]Lu-DWJ155
The PK analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. Vz will be determined by non-compartmental methods.
Measured: From pre-dose up to 168 hours after the end of the infusion on Day 1
Terminal half-life (T1/2) of [177Lu]Lu-DWJ155
The PK analysis will be performed based on decay-corrected blood radioactivity concentration data converted to mass units. T1/2 will be determined by non-compartmental methods.
Measured: From pre-dose up to 168 hours after the end of the infusion on Day 1
Urinary excretion of [177Lu]Lu-DWJ155
The PK analysis will be performed based on decay-corrected urine radioactivity concentration data converted to mass units. Urinary excretion will be derived based on the percentage of injected dose excreted in urine in each collection interval and overall.
Measured: From pre-dose up to 72 hours after the end of the infusion on Day 1
Renal clearance (CLr) of [177Lu]Lu-DWJ155
The PK analysis will be performed based on decay-corrected blood and urine radioactivity concentration data converted to mass units. CLr will be determined by non-compartmental methods.
Measured: From pre-dose up to 72 hours after the end of the infusion on Day 1
Absorbed radiation dose in selected organs, tumor lesions and total body of [177Lu]Lu-DWJ155
Single Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) images will be acquired to assess total body, organ and tumor lesion dosimetry.
Measured: Up to 168 hours after the end of the infusion on Day 1
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) of [68Ga]Ga-DWJ155:
Incidence and severity of AEs and SAEs, including changes in laboratory values, vital signs, echocardiograms (ECGs), and cardiac imaging qualifying and reported as AEs.
Measured: Up to 3 days
Standard uptake values (SUVs) in normal tissues and selected tumor lesions of [68Ga]Ga-DWJ155
68Ga-DWJ155 positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance imaging (PET/MRI) imaging assessments will be performed to derive SUVs in normal tissues and selected tumor lesions.
Measured: Up to approximately 1.5 hours after the end of infusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2026
- Study start16 Jun 2026
- Primary completion24 May 2032 (estimated)
- Study completion24 May 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 156 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07660055
- Sponsor's protocol ID
- CFML539A12101
- Other IDs
- 2024-518348-19
- Status last verified
- Aug 2026
- First submitted
- 15 Jun 2026
- Last updated
- 27 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.